GLP-1 treatment to slow small blood-vessel brain damage
Part of Brain & nervous system, Heart & circulation clinical trials.
This Phase 2 study tests whether a GLP-1–like medicine can slow worsening “small vessel” disease changes in the brain and related walking and thinking problems. It aims to see if the treatment can prevent progression in people who already show early brain changes on MRI.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are Chinese and between 55 and 80 years old
- Your brain MRI shows early small-vessel–type white-matter changes (not from other rare diseases)
- You can walk at least limited distances and score enough on a walking assessment
- Your thinking test (MoCA) is below 25 but not in a dementia range
- You can safely take a GLP-1–type medicine (no related thyroid/pancreas/eye allergy issues)
- You can complete MRI scans safely (kidney function and implants/metal are compatible)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug that targets a protein called TSPO to see if it can improve the function of the cells lining the small blood vessels in the brain of people with cerebral small vessel disease. It may help with mild memory or thinking problems.
This study looks at brain activity and walking in people who have small vessel disease, a condition where tiny blood vessels in the brain are damaged. It uses EEG and MRI scans to understand how the brain controls walking, which may help improve future treatments for gait problems.
This study follows people with cerebral small vessel disease (a condition where the small blood vessels in the brain are damaged) over time to learn more about how it progresses and how it affects people. Participating involves regular check-ins and MRI scans to monitor your health.
This trial looks at how to slow cognitive decline and early dementia in people with a specific kind of “silent” blood vessel damage in the brain seen on scans. It may help identify whether targeting this hidden condition can protect thinking and memory over time.
This study tests whether adding a treatment that improves blood vessel and insulin function can make the standard Alzheimer's medication work better for people with mild Alzheimer's or mild cognitive impairment.
This study follows people with small vessel brain disease to understand how it changes over time. You may join if you've had an MRI showing this type of brain change and are able to take care of yourself daily.
Hear when a new Cerebral Small Vessel Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.